The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Ibrutinib and rituximab shows superior PFS vs. FCR in CLL
Jacqueline Barrientos, MD, Northwell Health, New York, NY, discusses the extended follow-up results from the E1912 trial (NCT02048813) comparing chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab (FCR) to the combination of ibrutinib and rituximab (IR) for previously untreated chronic lymphocytic leukemia (CLL) patients. With extended follow-up, the combination of ibrutinib and rituximab continues to provide superior progression-free survival compared to FCR for younger patients with previously untreated CLL. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
